Page 97 - Read Online

Saleh et al. Improvement of prostate cancer detection

29. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, individual patient data from 12 prospective studies. Ann Intern Med
Abrahamsson P. Neuroendocrine differentiation is not prognostic of 2008;149:461-71, W83-8.
failure after radical prostatectomy but correlates with tumor volume. 37. Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y, Mori
Urology 2000;56:1011-5. M, Sakauchi F, Washio M, Kubo T, Suzuki K, Wakai K, Nakachi K,
30. Zitella A, Berruti A, Destefanis P, Mengozzi G, Torta M, Ceruti C, Tajima K, Ito Y, Inaba Y, Tamakoshi A; JACC Study Group. Prostate
Casetta G, Mosca A, Greco A, Rolle L, Aimo G, Aroasio E, Tizzani A, cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-
Dogliotti L, Fontana D; Gruppo Oncologico Urologico Piemontese binding protein-3: a nested case-control study in large scale cohort
(GOUP). Comparison between two commercially available study in Japan. Asian Pac J Cancer Prev 2009;10 Suppl:57-61.
chromogranin A assays in detecting neuroendocrine differentiation 38. Pham TM, Fujino Y, Kikuchi S, Tamakoshi A, Yatsuya H, Matsuda
in prostate cancer and benign prostate hyperplasia. Clin Chim Acta S, Yoshimura T; JACC Study Group. A nested case-control study of
2007;377:103-7. stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2
31. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. and IGF-binding protein (IGFBP)-3. Eur J Cancer 2007;43:1611-6.
Horm Metab Res 1994;26:81-4. 39. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate
32. Corrêa LL, Lima GA, Paiva HB, Silva CM, Cavallieri SA, Miranda tissue: morphogenesis, proliferation, and androgen receptor status.
LC, Gadelha MR. Prostate cancer and acromegaly. Arq Bras Prostate Suppl 1998;8:18-22.
Endocrinol Metabol 2009;53:963-8. 40. Sciarpa A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M,
33. Kehinde EO, Akanji AO, Mojiminiyi OA, Bashir AA, Daar AS, D’Eramo G, Di Silverio F. Clinical under staging in patients with
Varghese R. Putative role of serum insulin-like growth factor-1 (IGF- prostate adenocarcinoma submitted to radical prostatectomy:
1) and IGF binding protein-3 (IGFBP-3) levels in the development
of prostate cancer in Arab men. Prostate Cancer Prostatic Dis predictive value of serum chromogranin A. Prostate 2004;58:421-8.
2005;8:84-90. 41. Appetecchia M, Meçule A, Pasimeni G, Iannucci CV, De Carli P,
34. Djavan B, Waldert M, Seitz C, Marberger M. Insulin-like growth Baldelli R, Barnabei A, Cigliana G, Sperduti I, Gallucci M. Incidence
factors and prostate cancer. World J Urol 2001;19:225-33. of high chromogranin A serum levels in patients with non-metastatic
35. Endogenous Hormones and Breast Cancer Collaborative Group, Key prostate adenocarcinoma. J Exp Clin Cancer Res 2010;29:166.
TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 42. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH,
1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: Roobol MJ, Pols HA, Lamberts SW, Schröder FH. Circulating free
pooled individual data analysis of 17 prospective studies. Lancet insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding
Oncol 2010;11:530-42. protein-3 levels do not predict the future risk to develop prostate
36. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, cancer: results of a case-control study involving 201 patients within a
Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, population-based screening with a 4-year interval. J Clin Endocrinol
Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen Metab 2004;89:4391-6.
MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, 43. Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P,
Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Michel MS. IGF-II serum levels increase discrimination between
Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, benign prostatic hyperplasia and prostate cancer and improve the
Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth predictive value of PSA in clinical staging. Eur Urol 2006;49:286-
factors, their binding proteins, and prostate cancer risk: analysis of 92; discussion 292.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ May 24, 2017 89